Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
Novo Nordisk Is Throwing Down The Gauntlet In Weight Loss As Eli Lilly Ramps Up
09:04am, Wednesday, 02'nd Nov 2022
Novo Nordisk is planning to boost production for weight-loss shot Wegovy as Eli Lilly angles for approval. NVO stock surged Wednesday.
Eli Lilly and Co (LLY) Q3 2022 Earnings Call Transcript
04:08pm, Tuesday, 01'st Nov 2022
Eli Lilly and Co (NYSE:LLY ) Q3 2022 Earnings Conference Call November 1, 2022 9:00 AM ET Company Participants Joe Fletcher - SVP, IR David Ricks - Chairman, CEO & President Anat Ashkenazi - SVP & CFO
Lilly's new diabetes drug doubled sales expectations. It may also be used to treat obesity
02:58pm, Tuesday, 01'st Nov 2022
Eli Lilly & Co. Inc.'s LLY, -3.40% steady transformation into a developer of both cutting-edge diabetes and obesity treatments is well underway.
Lilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 View
02:19pm, Tuesday, 01'st Nov 2022
Eli Lilly's (LLY) earnings and sales surpass third-quarter estimates. The company lowers 2022 financial view for the third time this year.
Eli Lilly Stock Slips After Earnings Beat. Forecast Is the Issue.
12:14pm, Tuesday, 01'st Nov 2022
The pharmaceutical group slashed its full-year fiscal guidance for the third quarter in a row. Investors are also looking at updates on the much-hyped drug Mounjaro.
Pfizer beats estimates, Eli Lilly cuts outlook
10:39am, Tuesday, 01'st Nov 2022
Yahoo Finance's Anjalee Khemlani joins the Live show to discuss quarterly earnings for Pfizer and Eli Lilly.
Eli Lilly (LLY) Q3 Earnings and Revenues Beat Estimates
09:02am, Tuesday, 01'st Nov 2022
Lilly (LLY) delivered earnings and revenue surprises of 0.51% and 0.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lilly's new Type 2 diabetes drug had $187 million in sales in the third quarter
07:30am, Tuesday, 01'st Nov 2022
Eli Lilly & Co. Inc. LLY, +0.61% said its new Type 2 diabetes treatment Mounjaro brought in $187.3 million in sales in the third quarter of the year, beating the FactSet consensus of $183.0 million. I
Eli Lilly Earnings Beat but the Stock Falls as Forecast Is Cut
07:11am, Tuesday, 01'st Nov 2022
Eli Lilly slashed its full-year fiscal guidance for the third quarter in a row. Investors are also looking at updates on the much-hyped drug Mounjaro.
Lilly beats adjusted earnings and revenue target but trims its 2022 view
06:54am, Tuesday, 01'st Nov 2022
Eli Lilly & Co. LLY, +0.61% shares dipped 1.1% in premarket trades on Tuesday after the drug maker trimmed its 2022 earnings outlook, but posted stronger-than-expected third-quarter results. Lilly's n
Dow Notches Strongest Month of Trading Since 1976
07:34pm, Monday, 31'st Oct 2022
At +11%, it's the best October on record for the blue-chip index and the strongest single-month of trading since the U.S. Bicentennial.
Eli Lilly Q3 Preview: Can Shares Stay Hot?
05:18pm, Friday, 28'th Oct 2022
LLY shares have been a bright spot in an otherwise dim market in 2022, outperforming the S&P 500 across several timeframes.
Three buys and a bail: AbbVie, Eli Lilly, Humana and Moderna
02:25pm, Friday, 28'th Oct 2022
Gina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss three stocks Sanchez is interested in buying and one the strategist is bailing on.
Eli Lilly Is Now Worth More Than Nvidia, A Correction Seems Highly Likely
12:33pm, Friday, 28'th Oct 2022
Eli Lilly stock has defied the bear market of 2022 and is now up more than 30% year-to-date after a recent breakout. Thanks to hype around several drugs in the company's pipeline, primarily donanemab
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
10:32am, Tuesday, 25'th Oct 2022
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
